Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,375 Cr
verified against source
Revenue YoY
20%
reported change
EBITDA
₹382 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Ajanta Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 1,375 crore (+20% YoY) and EBITDA of INR 382 crore (+19% YoY). PAT grew 18% YoY to INR 274 crore. Growth was led by the US generics business (+52% YoY to INR 399 crore) driven by new product launches and market share gains, and India branded business (+19% YoY to INR 409 crore) outperforming IPM. Africa branded grew 33% YoY, while Asia branded declined 9% YoY due to softer traction in select markets. Management maintained EBITDA margin guidance of 27%±1% for FY26 and expects gross margin around 78%±1%. Key strategic initiatives include GLP-1 partnership with Biocon for 26 countries (launch from FY27-28) and active M&A pipeline with INR 1,000+ crore earmarked. Risk: Asia branded recovery may take longer than expected if market softness persists.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated EBITDA margin guidance of 27%±1% for the full year, excluding mark-to-market forex impact.
- Gross margin expected to remain around 78%±1% for the full year.
- Capital expenditure for 9M stood at INR 235 crore; full year guidance of around INR 300 crore.
- Management expects US generics to post double-digit growth in FY27, though growth rate may moderate from FY26 levels.
Risks flagged
- Asia branded declined 9% YoY due to softer traction in certain markets; management expects recovery from Q4 but no specific timeline.
- Analyst raised concern about aggressive competition in India for GLP-1; management acknowledged 15-20+ competitors expected.
- Mark-to-market forex loss of INR 61 crore in 9M impacted EBITDA margin; management excluded it from guidance but risk remains.
- Management mentioned potential entry into Latin America and active M&A pipeline; execution and integration risks are high.
Key quotes
- We continue to outperform the Indian pharmaceutical market by 28% as per IQVIA MAT December 2025, with Ajanta delivering an impressive growth of 11% compared to IPM's 9%.
- We are actively looking for the acquisition also, and we are as, as it was there in the news that we are here INR 1,000+ crore for that.
- We've never seen a launch of a product like this in the longest time. Already, globally, it's become, I think, what? $35-$40 billion and $25 billion each, $50 billion. And it's still growing at 25%-30%.
Research modules